Pilot aims to slash Kids' cancer treatment time from days to hours

This study is testing if a standard immunotherapy drug for high-risk neuroblastoma, a serious childhood cancer, can be safely given over a much shorter time. Currently, the drug (dinutuximab) is infused over 10-20 hours for several days, requiring a hospital stay. Researchers want to see if giving it over 4 hours or less is feasible and tolerable for children. If successful, this could allow treatment in an outpatient clinic, reducing hospital time and burden for patients and families.